HRP20090194T1 - Suha granulirana kompozicija koja sadrži emtricitabin i tenofovir df - Google Patents

Suha granulirana kompozicija koja sadrži emtricitabin i tenofovir df

Info

Publication number
HRP20090194T1
HRP20090194T1 HR20090194T HRP20090194T HRP20090194T1 HR P20090194 T1 HRP20090194 T1 HR P20090194T1 HR 20090194 T HR20090194 T HR 20090194T HR P20090194 T HRP20090194 T HR P20090194T HR P20090194 T1 HRP20090194 T1 HR P20090194T1
Authority
HR
Croatia
Prior art keywords
tenofovir
emtricitabin
composition containing
dry granulated
granulated composition
Prior art date
Application number
HR20090194T
Other languages
English (en)
Croatian (hr)
Inventor
C. Dahl Terrence
M. Menning Mark
Oliyai Reza
Yang Taiyin
Original Assignee
Gilead Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37532912&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20090194(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences filed Critical Gilead Sciences
Publication of HRP20090194T1 publication Critical patent/HRP20090194T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/002—Compounding apparatus specially for enteral or parenteral nutritive solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HR20090194T 2005-06-13 2006-06-13 Suha granulirana kompozicija koja sadrži emtricitabin i tenofovir df HRP20090194T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69001005P 2005-06-13 2005-06-13
US77135306P 2006-02-07 2006-02-07
PCT/US2006/023222 WO2006135932A2 (en) 2005-06-13 2006-06-13 Stable fixed-dose formulations containing a combination of antivirals, method for producing thereof using dry granulation

Publications (1)

Publication Number Publication Date
HRP20090194T1 true HRP20090194T1 (hr) 2009-07-31

Family

ID=37532912

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090194T HRP20090194T1 (hr) 2005-06-13 2006-06-13 Suha granulirana kompozicija koja sadrži emtricitabin i tenofovir df

Country Status (21)

Country Link
US (3) US20070077295A1 (pl)
EP (1) EP1890681B1 (pl)
JP (3) JP5409001B2 (pl)
CN (2) CN101222914B (pl)
AR (1) AR054511A1 (pl)
AT (1) ATE419839T1 (pl)
AU (1) AU2006257794B2 (pl)
CA (1) CA2611520C (pl)
CY (1) CY1108973T1 (pl)
DE (1) DE602006004731D1 (pl)
DK (1) DK1890681T3 (pl)
ES (1) ES2320039T3 (pl)
HR (1) HRP20090194T1 (pl)
MX (1) MX2007015764A (pl)
NZ (1) NZ564045A (pl)
PL (1) PL1890681T3 (pl)
PT (1) PT1890681E (pl)
RS (1) RS50812B (pl)
SI (1) SI1890681T1 (pl)
TW (1) TWI375560B (pl)
WO (1) WO2006135932A2 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05007016A (es) 2003-01-14 2005-09-12 Gilead Sciences Inc Composiciones y metodos para terapia antiviral de combinacion.
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
SG183007A1 (en) 2006-07-07 2012-08-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
PL3150586T3 (pl) 2007-02-23 2020-06-01 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości środków terapeutycznych
HRP20151357T1 (hr) 2008-05-02 2016-01-29 Gilead Sciences, Inc. Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CN102281869A (zh) * 2008-11-21 2011-12-14 阿尔迪默菲克斯技术有限责任公司 替诺福韦、恩曲他滨和依法韦仑的湿法制粒
PT2376088T (pt) 2008-12-23 2017-05-02 Gilead Pharmasset Llc Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
KR20110098849A (ko) 2008-12-23 2011-09-01 파마셋 인코포레이티드 뉴클레오시드 유사체
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
DK2393485T3 (en) 2009-02-06 2015-10-26 Gilead Sciences Inc Bilayer COVERING ELVITEGRAVIR, COBICISTAT, emtricitabine and tenofovir
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
EP3315124B1 (en) * 2009-11-13 2021-01-06 Astrazeneca AB Bilayer tablet formulations
EP2377862A1 (en) * 2010-03-29 2011-10-19 Esteve Química, S.A. Process for obtaining emtricitabine
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
SG10201509521WA (en) * 2010-11-19 2015-12-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
US9303918B2 (en) * 2013-03-15 2016-04-05 Monosol Rx, Llc Process for drying a wet film with control of loss on drying
HK1220390A1 (zh) 2013-08-29 2017-05-05 Teva Pharmaceutical Industries Ltd. 包括恩曲他滨，替诺福韦，达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂
IN2013CH05288A (pl) * 2013-11-18 2015-09-11 Aurobindo Pharma Ltd
CA2942877A1 (en) 2014-04-08 2015-10-15 Nitzan SHAHAR Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN105125511A (zh) * 2014-05-30 2015-12-09 北京星昊医药股份有限公司 一种富马酸替诺福韦酯片及其制备方法
PT3316868T (pt) 2015-06-30 2020-04-21 Gilead Sciences Inc Formulações farmacêuticas compreendendo tenofovir e emtricitabina
CN106539807B (zh) * 2015-09-21 2020-06-26 四川海思科制药有限公司 一种稳定的药物组合物及其制备方法
CN106749409A (zh) * 2016-11-30 2017-05-31 宁波美诺华药业股份有限公司 一种替诺福韦酯富马酸盐二聚体杂质的合成方法
US10561614B2 (en) 2017-01-27 2020-02-18 Steerlife India Private Limited Tenofovir granules
RU2644156C1 (ru) 2017-02-28 2018-02-08 Александр Васильевич Иващенко Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения
RU2662160C9 (ru) * 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
TR201713954A2 (tr) * 2017-09-20 2019-04-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari
WO2021091498A1 (en) * 2019-11-06 2021-05-14 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. Pharmaceutical compositions comprising tenofovir and emtricitabine
CN111407736A (zh) * 2020-03-30 2020-07-14 苏州弘森药业股份有限公司 一种富马酸替诺福韦二吡呋酯片的制备工艺
CN119139247A (zh) * 2024-09-05 2024-12-17 安徽贝克生物制药有限公司 一种恩曲他滨丙酚替诺福韦复方片及制备方法

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH389608A (de) 1960-01-19 1965-03-31 Sandoz Ag Verfahren zur Herstellung von neuen Äthern
US3524846A (en) * 1967-06-02 1970-08-18 Syntex Corp Process for the didealkylation of phosphonate esters
US3622677A (en) * 1969-07-07 1971-11-23 Staley Mfg Co A E Compressed tablets containing compacted starch as binder-disintegrant ingredient
CH531000A (de) * 1970-03-11 1972-11-30 Sandoz Ag Verfahren zur Herstellung neuer Benzocycloheptathiophene
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
US4003878A (en) * 1972-12-07 1977-01-18 Avtex Fibers Inc. Method of preparing an alkali-metal salt of an alkoxysulfonated benzoic acid glycol ester
GB1523865A (en) 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
DE2645710C2 (de) * 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
US4384005A (en) * 1980-09-26 1983-05-17 General Foods Corporation Non-friable, readily-soluble, compressed tablets and process for preparing same
GB2111043B (en) 1980-12-12 1985-02-06 Ciba Geigy Ag Novel cephalosporin esters
US4355032B2 (en) * 1981-05-21 1990-10-30 9-(1,3-dihydroxy-2-propoxymethyl)guanine as antiviral agent
JPS5879983A (ja) * 1981-11-06 1983-05-13 Kanebo Ltd 新規なベンズイミダゾ−ル誘導体、その製造法およびその医薬組成物
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4476248A (en) * 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
DE3485225D1 (de) * 1983-08-18 1991-12-05 Beecham Group Plc Antivirale guanin-derivate.
US5155268A (en) * 1984-05-04 1992-10-13 The Upjohn Company Antiarrhythmic N-aminoalkylene alkyl and aryl sulfonamides
EP0182024B1 (en) 1984-09-20 1991-04-03 Beecham Group Plc Purine derivatives and their pharmaceutical use
CS263951B1 (en) * 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS263952B1 (en) 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
IL84477A (en) 1986-11-18 1995-12-08 Bristol Myers Squibb Co History of Phosphonomethoxyalkylene Purinopyrimidine and Pharmaceutical Preparations Containing Them
NL8720745A (nl) 1987-01-20 1988-12-01 Stanford Res Inst Int Nieuwe antivirale middelen.
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
ZA885709B (en) 1987-08-19 1989-04-26 Fujisawa Pharmaceutical Co Novel crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid(syn isomer)
US5466806A (en) 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
CA2001715C (en) 1988-11-14 1999-12-28 Muzammil M. Mansuri Carbocyclic nucleosides and nucleotides
UA45942A (uk) 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5827727A (en) 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ATE131825T1 (de) 1990-06-13 1996-01-15 Arnold Glazier Phosphorylierte prodrugs
US5177064A (en) * 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
US5356886A (en) 1990-07-19 1994-10-18 Beecham Group P.L.C. Antiviral phosphono-alken derivatives of purines
FI930552A7 (fi) * 1990-08-10 1993-02-22 Rega Stichting Uusi menetelmä nukleotidien valmistamiseksi
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
CA2054126A1 (en) 1990-10-26 1992-04-27 Michiyuki Sendai Cephem compounds, their production and use
US5587480A (en) 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US5208221A (en) * 1990-11-29 1993-05-04 Bristol-Myers Squibb Company Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives
GB9026164D0 (en) 1990-12-01 1991-01-16 Beecham Group Plc Pharmaceuticals
US5179104A (en) 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
NZ241625A (en) 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
WO1992020344A1 (en) 1991-05-16 1992-11-26 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
GB9110874D0 (en) 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
AU4356693A (en) 1992-06-23 1994-01-24 Yamanouchi Pharmaceutical Co., Ltd. Novel crystal of monohydrate of heterocyclic bis(phosphonic acid) derivative
US5532225A (en) 1992-07-31 1996-07-02 Sri International Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods
US5432172A (en) 1992-08-03 1995-07-11 The Research Foundation Of State University Of New York Biological applications of alkaloids derived from the tunicate Eudistoma sp.
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
EP0684953A4 (en) * 1993-02-03 1999-12-22 Gensia Inc ADENOSINE KINASE INHIBITORS COMPRISING LYXOFURANOSYL DERIVATIVES.
US5514798A (en) * 1993-06-02 1996-05-07 Gilead Sciences, Inc. Method and cyclic carbonates for nucleotide analogues
GB9311709D0 (en) 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
ATE199906T1 (de) 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
AU691527B2 (en) 1993-09-17 1998-05-21 Gilead Sciences, Inc. Nucleotide analogs
EP0719274A1 (en) 1993-09-17 1996-07-03 Gilead Sciences, Inc. Method for dosing therapeutic compounds
WO1995032957A1 (en) 1994-05-27 1995-12-07 Astra Aktiebolag Novel ethoxycarbonyloxymethyl derivatives of substituted benzimidazoles
US5514557A (en) 1994-06-06 1996-05-07 Genetic Testing Institute Inc. Method and kit for detecting antibodies specific for HLA and/or platelet glycoproteins
PE32296A1 (es) 1994-07-28 1996-08-07 Hoffmann La Roche Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables
US5512596A (en) * 1994-09-02 1996-04-30 Gilead Sciences, Inc. Aromatic compounds
US5684018A (en) 1994-12-13 1997-11-04 Merck & Co., Inc. Acyloxyisopropyl carbamates as prodrugs for amine drugs
US5618964A (en) * 1995-06-07 1997-04-08 Bristol-Myers Squibb Company Prodrug esters of phosphonosulfonate squalene synthetase inhibitors and method
US5733788A (en) 1996-07-26 1998-03-31 Gilead Sciences, Inc. PMPA preparation
CA2261619C (en) 1996-07-26 2006-05-23 Gilead Sciences, Inc. Nucleotide analogs
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US6121315A (en) * 1996-09-20 2000-09-19 Warner-Lambert Company Oral compositions containing a zinc compound
US6113920A (en) 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
EP1256585B1 (en) 1997-07-25 2004-09-29 Gilead Sciences, Inc. Process for preparing 9-(2-(diethylphosphonomethoxy)ethyl)-adenine
CO4970782A1 (es) 1997-11-13 2000-11-07 Merck & Co Inc Terapia combinada para el tratamiento del sida
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
CO5070643A1 (es) 1998-05-27 2001-08-28 Merck & Co Inc Formulacion en tabletas comprimidas
MXPA00012842A (es) * 1998-06-24 2004-06-22 Univ Emory Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.
DK1382343T3 (da) 1998-11-02 2010-04-26 Gilead Sciences Inc Kombinationsterapi til behandling af hepatitis B-virus
ES2250363T3 (es) * 2000-02-02 2006-04-16 Dorian Bevec Guanilhidrazonas aromaticas farmaceuticamente activas.
GEP20053504B (en) 2000-02-29 2005-05-10 Bristol Myers Squibb Co Low Dose Entecavir Pharmaceutical Composition and Use Thereof for Treatment of Hepatitis B
CZ304734B6 (cs) 2000-07-21 2014-09-10 Gilead Sciences, Inc. Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu
IL156447A0 (en) 2000-12-15 2004-01-04 Triangle Pharmaceuticals Inc Dapd combination therapy with inosine monophosphate dehydrogenase inhibitors
AU2002242096A1 (en) 2001-02-06 2002-08-19 The University Of Georgia Research Foundation, Inc. Novel compounds and methods for inhibiting/treating hiv infections and aids related symptoms
KR101150250B1 (ko) 2001-03-01 2012-06-12 아보트 래버러토리즈 시스-ｆｔｃ의 다형 및 기타 결정형
US20020187957A1 (en) * 2001-05-30 2002-12-12 Bruce Halstead Time release reverse transcriptase inhibitors
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US20030124186A1 (en) * 2001-11-27 2003-07-03 Hussain Munir A. Efavirenz tablet formulation having unique biopharmaceutical characteristics
CN101352421A (zh) 2002-01-16 2009-01-28 贝林格尔英格海姆法玛两合公司 一种制备基本上非结晶形式的替米沙坦的方法
AU2003210659A1 (en) * 2002-01-24 2003-09-02 Sangstat Medical Corporation Combination therapy for treatment of hiv infection
AU2003231765B9 (en) 2002-04-26 2010-01-28 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
CN100406017C (zh) 2002-12-09 2008-07-30 佐治亚大学研究基金会 用于对抗hiv抗性株的二氧戊环基胸腺嘧啶及其组合物
WO2004060355A1 (en) * 2002-12-26 2004-07-22 Pozen Inc. Multilayer Dosage Forms Containing NSAIDs and Triptans
MXPA05007016A (es) 2003-01-14 2005-09-12 Gilead Sciences Inc Composiciones y metodos para terapia antiviral de combinacion.
AU2004246837B2 (en) * 2003-06-06 2009-07-16 Ethypharm Orally-dispersible multilayer tablet
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
CN101142229A (zh) 2005-01-18 2008-03-12 阿德拉·N·沙克 通过与KAP相互作用而用于细胞周期调节的HTm4
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
US8232278B2 (en) 2005-06-24 2012-07-31 Gilead Sciences, Inc. Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C
ATE474560T1 (de) 2005-12-14 2010-08-15 Cipla Ltd Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit
GB0525898D0 (en) 2005-12-20 2006-02-01 Pharmo Bioscience As Screening compounds for activity in modulating chloride ion transport
WO2008087643A2 (en) 2007-01-16 2008-07-24 Proteologics Ltd Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors

Also Published As

Publication number Publication date
CY1108973T1 (el) 2014-07-02
US20140370102A1 (en) 2014-12-18
MX2007015764A (es) 2008-03-04
TWI375560B (en) 2012-11-01
ATE419839T1 (de) 2009-01-15
CA2611520C (en) 2011-11-29
HK1109861A1 (en) 2008-06-27
PL1890681T3 (pl) 2009-06-30
PT1890681E (pt) 2009-03-31
US20070077295A1 (en) 2007-04-05
CN104523713A (zh) 2015-04-22
EP1890681B1 (en) 2009-01-07
CA2611520A1 (en) 2006-12-21
SI1890681T1 (sl) 2009-06-30
JP2008546705A (ja) 2008-12-25
DE602006004731D1 (de) 2009-02-26
DK1890681T3 (da) 2009-04-20
CN101222914B (zh) 2015-10-07
JP2015007137A (ja) 2015-01-15
AR054511A1 (es) 2007-06-27
CN101222914A (zh) 2008-07-16
NZ564045A (en) 2011-05-27
JP2012062332A (ja) 2012-03-29
AU2006257794B2 (en) 2010-06-24
AU2006257794A1 (en) 2006-12-21
RS50812B (sr) 2010-08-31
ES2320039T3 (es) 2009-05-18
US20140037732A1 (en) 2014-02-06
WO2006135932A2 (en) 2006-12-21
JP5409001B2 (ja) 2014-02-05
TW200711652A (en) 2007-04-01
WO2006135932A3 (en) 2007-05-24
US8871271B2 (en) 2014-10-28
EP1890681A2 (en) 2008-02-27

Similar Documents

Publication Publication Date Title
HRP20090194T1 (hr) Suha granulirana kompozicija koja sadrži emtricitabin i tenofovir df
CY1126116T1 (el) Φαρμακευτικες συνθεσεις αποτελουμενες απο νιλοτινιμπη
TW200624120A (en) Stable tablet formulation
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
TW200744602A (en) Administration of dipeptidyl peptidase inhibitors
SG170087A1 (en) Pharmaceutical compositions
TW200716206A (en) Unitary pharmaceutical dosage form
GEP20094784B (en) Sustained release pharmaceutical formulations
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
CY1118180T1 (el) Μεθοδος για παρασκευη στερεας φαρμακευτικης συνθεσης
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
ZA200700397B (en) Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same
MY177386A (en) Drug formulations having improved pharmacokinetic properties
WO2007134158A3 (en) Granules comprising calcium carbonate, a binder and a porosity increasing agent, processes of manufacturing, use in therapy
TW200639156A (en) New compounds
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
MY149864A (en) Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties
WO2009135950A3 (en) Process for preparing a tablet containing excipients
PL1853232T3 (pl) Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania
WO2006134021A3 (en) Process for preparing tiotropium salts, tiotropium salts as such and pharmaceutical compositions thereof
ZA200506992B (en) Fibrate tablet and method for the production thereof
UA95274C2 (ru) Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления
ATE402706T1 (de) Im mund zerfallende pharmazeutische zusammensetzung mit risperidon
EA200700207A1 (ru) Твёрдая фармацевтическая композиция, включающая миртазапин
WO2007066200A3 (en) Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications